MAXIGESIC IVの薬剤に関する洞察と市場予測：2032年

MAXIGESIC IV（パラセタモール＋イブプロフェン）は、新規の特許取得済みデュアルモード非オピオイド疼痛治療薬であり、パラセタモール（米国ではアセトアミノフェンとして知られる）1,000mgとイブプロフェン300mgのユニークな組み合わせで、経口鎮痛薬の使用が制限されている患者の術後に病院で使用される輸液用です。この特別な組み合わせは、パラセタモールとイブプロフェンの1日最大投与量を可能にし、パラセタモールがフェニレフリンに作用するように設計されており、組み合わせるとフェニレフリンの血中への移行レベルが実質的に2倍になります。

MAXIGESICは熱を下げ、頭痛、片頭痛、緊張型頭痛、副鼻腔痛、歯痛、歯科処置、背部痛、咽頭痛、関節炎、テニス肘、生理痛、筋肉痛、リウマチ痛、風邪やインフルエンザに伴う痛みを一時的に和らげます。この医薬品は、パラセタモールとイブプロフェンのユニークな組み合わせで特許を取得しており、幅広い痛みの症状を迅速かつ効果的に緩和することが証明されています。

当レポートでは、米国におけるMAXIGESIC IV市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 急性疼痛に対するMAXIGESIC IVの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 MAXIGESIC IV市場評価

• 急性疼痛におけるMAXIGESIC IVの市場展望
• 米国の分析

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

• 参考文献
• レポート調査手法

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: MAXIGESIC IV, Clinical Trial Description, 2023
• Table 2: MAXIGESIC IV, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: MAXIGESIC IV Market Size in the US, in USD million (2019-2032)

List of Figures

• Figure 1: MAXIGESIC IV Market Size in the United States, USD million (2019-2032)

"MAXIGESIC IV Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MAXIGESIC IV for acute pain in the United States. A detailed picture of the MAXIGESIC IV for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the MAXIGESIC IV for acute pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MAXIGESIC IV market forecast analysis for acute pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain.

Drug Summary:

MAXIGESIC IV (paracetamol + ibuprofen), a novel, patented, dual mode-of-action non-opioid pain treatment, is a unique combination of paracetamol (known as acetaminophen in the US) 1,000 mg + ibuprofen 300 mg solution for infusion for use postoperatively in hospitals for patients for whom the use of oral analgesics is limited. This specific combination is designed to allow the maximum daily dose of paracetamol and ibuprofen and to allow for the effect of paracetamol on phenylephrine when combined, the level of phenylephrine crossing into the bloodstream effectively doubles.

MAXIGESIC reduces fever and temporarily relieves pain associated with headaches, migraines, tension headaches, sinus pain, toothache, dental procedures, backache, sore throat, arthritis, tennis elbow, period pain, muscular pain, rheumatic pain, aches and pains associated with colds and flu. The drug is a unique patented combination of paracetamol and ibuprofen, proven to provide fast and effective relief from a wide range of pain symptoms.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the MAXIGESIC IV description, mechanism of action, dosage and administration, research and development activities in acute pain.
• Elaborated details on MAXIGESIC IV regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MAXIGESIC IV research and development activities in acute pain across the United States.
• The report also covers the patents information with expiry timeline around MAXIGESIC IV.
• The report contains forecasted sales of MAXIGESIC IV for acute pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute pain.
• The report also features the SWOT analysis with analyst views for MAXIGESIC IV in acute pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MAXIGESIC IV Analytical Perspective by DelveInsight

In-depth MAXIGESIC IV Market Assessment

This report provides a detailed market assessment of MAXIGESIC IV for acute pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

MAXIGESIC IV Clinical Assessment

The report provides the clinical trials information of MAXIGESIC IV for acute pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MAXIGESIC IV dominance.
• Other emerging products for acute pain are expected to give tough market competition to MAXIGESIC IV and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MAXIGESIC IV in acute pain.
• Our in-depth analysis of the forecasted sales data of MAXIGESIC IV from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MAXIGESIC IV in acute pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of MAXIGESIC IV?
• What is the clinical trial status of the study related to MAXIGESIC IV in acute pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MAXIGESIC IV development?
• What are the key designations that have been granted to MAXIGESIC IV for acute pain?
• What is the forecasted market scenario of MAXIGESIC IV for acute pain?
• What are the forecasted sales of MAXIGESIC IV in the United States?
• What are the other emerging products available and how are these giving competition to MAXIGESIC IV for acute pain?
• Which are the late-stage emerging therapies under development for the treatment of acute pain?

Table of Contents

1. Report Introduction

2. MAXIGESIC IV Overview in Acute pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. MAXIGESIC IV Market Assessment

• 5.1. Market Outlook of MAXIGESIC IV in Acute pain
• 5.2. The United States Analysis
  • 5.2.1. Market Size of MAXIGESIC IV in the United States for Acute pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options